Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
Lin GA, Whittington MD, Nikitin D, Agboola F, McKenna A, Herron-Smith S, Pearson SD, Campbell J
Record ID 32018005194
English
Details
Project Status:
Completed
Year Published:
2023
URL for published report:
https://icer.org/wp-content/uploads/2022/04/ICER_MS_Final_Evidence_Report_022123.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Cost-Effectiveness Analysis
- Antibodies, Monoclonal
- Sphingosine 1 Phosphate Receptor Modulators
- Fingolimod Hydrochloride
- Fumarates
- Natalizumab
- Rituximab
Contact
Organisation Name:
Institute for Clinical and Economic Review
Contact Address:
101 Merrimac St., 10th FL., Boston MA, USA 02114, Tel: (617) 724-4445 , Fax: (617) 726-9414
Contact Name:
info@icer-review.org
Contact Email:
info@icer-review.org
Copyright:
<p>Institute for Clinical and Economic Review (ICER)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.